PharmaCyte Biotech, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for PMCB, updated each market day.
PMCB AI Sentiment
AI sees no strong directional signal for PharmaCyte Biotech, Inc. Common Stock stock over the next 10 market days.
Prediction date: Aug. 7, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About PharmaCyte Biotech, Inc. Common Stock
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.
Sector
Exchange
Market Cap
$6,335,106
Cap Tier
Employees
2
Headquarters
LAS VEGAS, NV
Listed Since
Sept. 11, 2003
Website
PMCB Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
PMCB Volatility
PharmaCyte Biotech, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
